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Key Messages
1. Among hepatitis B virus 
carriers, infection with 
genotype C significantly 
increases the risk of developing 
hepatocellular cancer compared 
to those without this genotype. 
2. Among hepatitis C virus 
carriers, infection with 
genotype 1b increases the risk 
of hepatocellular cancer two-
fold compared to controls 
without this genotype.
3. Such increased risk should 
be explained as risk over 
and above the existing risk 
associated with each infection.
4. Hepatitis C virus genotypes 
1a and 2a are associated with 
decreased risk of hepatocellular 
cancer. 
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Introduction
Hepatitis B and C are common, serious infectious diseases in both developing 
and developed countries, affecting over one third of the world’s population. The 
prevalence of hepatitis B seropositivity in the adult population of Hong Kong 
ranges from 4 to 10%.1 A significant proportion of these subjects develop chronic 
hepatitis.2 It is not clear which of these subgroups of the population are at risk of 
chronic hepatitis and its complications. 
 Different genotypes of hepatitis B virus (HBV) or hepatitis C virus (HCV) 
may play a role in determining which groups of the population are at increased risk 
of developing hepatocellular cancer (HCC).3,4 The results remain controversial 
with regard to which genotype is dominant and the magnitude of the increased 
risk of HCC (if any).3,4 Knowing which genotype predisposes patients to HCC 
can help target populations for monitoring and/or early intervention, so as to 
achieve an early diagnosis and prolong life.
 
 This study aimed to (1) review the literature on HBV/HCV infection and 
genotypes and their association with HCC, and (2) estimate the magnitude of risk 
of HCC associated with HBV/HCV infection and different genotypes.
Methods
This study was conducted from January 2004 to July 2005. A comprehensive 
computerised literature search was conducted in July 2005 from the databases of 
MEDLINE, PubMed, EMBASE, and CANCERLIT, using various combinations 
of the terms: hepatitis, hepatitis B, hepatitis C, hepatitis B virus, hepatitis C virus, 
HBV, HCV, genotype(s), hepatocellular carcinoma, liver neoplasms, liver cancer, 
incidence, mortality, death rate, epidemiologic studies, case-control study, and 
cohort study. Links to related citations were also reviewed to identify other 
potentially relevant studies. To maximise the yield from the literature search, 
a manually recursive search of relevant articles, the reference list of retrieved 
articles, and meeting abstracts was also performed. 
 Studies included were (1) all observational studies (case-control and cohort) 
that provide age-matched controls, (2) studies with data on genotypes of HBV 
or HCV in patients with HCC, (3) documented diagnosis of HCC, and (4) all 
genotyping methods and all languages. Studies without raw data for retrieval as 
well as duplicate publications were excluded.
 Validity of all included studies was critically appraised, according to the 
guidelines for reading case-control studies.5 These guidelines entailed (1) an 
explicit description of the characteristics of cases and controls, how they were 
selected, and whether they were matched for age, gender, residence, and other 
factors; (2) information on the detection of HBV/HCV genotypes and how 
HCC was diagnosed; (3) data collection, analytic methods, sample size; and 
(4) the quality of data presentation. This assessment process was conducted by 
two independent reviewers. As the use of quality scoring in meta-analyses is 
controversial,6 no score was given during the quality assessment. 
 Odds ratios (OR) and 95% confidence intervals (CI) of developing HCC 
in relation to genotypes of HBV/HCV infection were calculated using either a 
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fixed- or random-effects model, depending on the result of 
homogeneity tests. Between-study heterogeneity was tested 
using the Cochran method. A p value of <0.1 was considered 
statistically significant for the test of homogeneity. 
Results
A total of 869 potentially relevant citations were generated; 
83 studies were included.
Hepatitis B virus genotypes and risk of 
hepatocellular cancer
There were 20 case-control and 4 cohort studies (involving 
865 cases of HCC and 5858 controls) to provide raw data 
on the association between HBV genotypes and the risk of 
developing HCC. 
 Regarding the HBV genotype A and HCC, 16 case-
control and one cohort studies (involving 739 cases and 
5002 controls) were analysed. The prevalence of genotype 
A was 4.74% (35/739) among cases and 5.74% (287/5002) 
among controls, yielding an OR of 1.29 (95% CI, 0.84-
1.97). The test of homogeneity was non-significant (Q 
Cochran=13.94, df=16, p=0.60). This suggested that 
patients harbouring HBV genotype A did not confer 
significant additional risk of developing HCC compared to 
those carrying HBV alone.
 Regarding the HBV genotype B and HCC, 18 case-
control and three cohort studies (involving 825 cases 
and 5426 controls) were analysed. The prevalence of 
genotype B was 24.6% (203/825) among cases and 25.9% 
(1406/5426) among controls, yielding an OR of 0.62 (95% 
CI, 0.45-0.86). This suggested that patients infected with 
HBV genotype B were at reduced risk of developing HCC 
compared to those without this genotype.
 Regarding the HBV genotype C and HCC, 18 case-
control and three cohort studies (involving 825 cases 
and 5426 controls) were analysed. The prevalence of 
genotype C was 64.6% (533/825) among cases and 66.7% 
(3618/5426) among controls, yielding an OR of 1.37 (95% 
CI, 1.12-1.68). This indicated that patients harbouring 
HBV genotype C were at increased risk of developing HCC 
compared to those without this genotype.
 Regarding the HBV genotype D and HCC, 11 case-
control and one cohort studies (involving 443 cases and 
2218 controls) were analysed. The prevalence of HBV 
genotype D was 9.5% (42/443) among cases and 17.99% 
(399/2218) among controls, yielding an OR of 0.74 (95% 
CI, 0.31-1.79). This suggested that HBV genotype D was 
not related to the development of HCC.
Hepatitis C virus genotypes and risk of 
hepatocellular cancer
There were 46 case-control and 13 cohort studies (involving 
2000 cases of HCC and 10 974 controls) to provide raw 
data on the association between HCV genotypes and the 
risk of developing HCC.
 Regarding the HCV genotype 1 and HCC, six case-
control and three cohort studies (involving 153 HCC cases 
and 1249) controls were analysed. The prevalence of HCV 
genotype 1 was 15.0% (23/153) among cases and 39.3% 
(491/1249) among controls, yielding an OR of 0.77 (95% 
CI, 0.43-1.40).
 Regarding the HCV genotype 1a and HCC, 32 case-
control and six cohort studies (involving 1317 cases and 
7116 controls) were analysed. The prevalence of HCV 
genotype 1a was 3.6% (47/1317) among cases and 6.7% 
(478/7116) among controls, yielding an OR of 0.53 (95% 
CI, 0.38-0.75). This suggested that patients harbouring 
the HCV genotype 1a had a significantly lower risk 
of developing HCC compared to those without this 
genotype.
 Regarding the HCV genotype 1b and HCC, 44 case-
control and 11 cohort studies (involving 1962 cases and 
10291 controls) were analysed. The prevalence of HCV 
genotype 1b was 72.3% (1419/1962) among cases and 
59.4% (6133/10291) among controls, yielding an OR of 
1.97 (95% CI, 1.63-2.37). This suggested that the HCV 
genotype 1b was associated with a significantly increased 
risk of developing HCC.
 Regarding the HCV genotype 2 and HCC, nine case-
control and five cohort studies (involving 185 cases and 
1809 controls) were analysed. The prevalence of HCV 
genotype 2 was 10.6% (44/417) among cases and 10.2% 
(185/1809) among controls, yielding an OR of 0.721 (95% 
CI, 0.47-1.096). 
 Regarding the HCV genotype 2a and HCC, 29 case-
control and five cohort studies (involving 1276 cases and 
7193 controls) were analysed. The prevalence of HCV 
genotype 2a was 12.1% (127/1053) among cases and 17.7% 
(1276/7193) among controls, yielding an OR of 0.78 (95% 
CI, 0.63-0.96). 
 Regarding the HCV genotype 2b and HCC, 26 case-
control and four cohort studies (involving 275 cases and 
5727 controls) were analysed. The prevalence of HCV 
genotype 2b was 2.9% (34/1174) among cases and 4.8% 
(275/5731) among controls, yielding an OR of 0.92 (95% 
CI, 0.67-1.39).
Discussion
Only a minority of patients with HBV or HCV infection 
develop HCC, despite the high prevalence of such infection. 
Identifying different genotypes of HBV/HCV helps explain 
why some patients are prone to developing HCC. No 
quantitative systematic review of the association between 
HBV/HCV genotypes and HCC has been published.
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 Although eight HBV genotypes have been identified, 
only data for genotypes A to D were adequate for a 
meaningful meta-analysis. For HBV genotype A, no 
significantly difference in the sero-frequency was noted. 
This suggested that genotype A was not common among 
patients with HBV infection, and not associated with the 
development of HCC. It neither increased nor decreased the 
risk of HCC among HBV carriers. For HBV genotypes B 
and D, they were also not associated with the development 
of HCC. Patients with HBV genotype C were at increased 
risk of developing HCC compared to those without this 
genotype. As HBV genotype C is most commonly found 
in South East Asia, where the prevalence of HCC is high, 
the magnitude of risk of developing HCC might have been 
underestimated due to a high background prevalence of 
HBV genotype C in HBV carriers without HCC. Therefore, 
the observed risk ratio of 1.37 should be explained as the 
risk for HCC over and above any existing risk associated 
with HBV infection. 
 The prevalence of HCV infection has increased in the 
last two decades as a result of increasing rates of drug 
abuse and transfusion of contaminated blood and blood 
products. Among HCV-infected patients, only 3.6% of the 
HCC patients and 6.7% of the controls were sero-positive 
for genotype 1a. Therefore, the clinical importance of 
HCV genotype 1a in relation to HCC is unclear. Further 
studies are needed to examine the clinical importance of 
this finding. For patients with HCV genotype 1b, they were 
at increased risk (nearly two-fold) of developing HCC than 
those without this genotype. A significantly decreased risk 
ratio was observed for HCV genotype 2a, but not for HCV 
genotypes 2 and 2b, suggesting that genotypes 2 and 2b 
had a lesser role, if any, in the development of HCC among 
HCV-infected patients.
 There were several limitations to the current meta-
analysis. We focused on individual genotypes and did 
not take into consideration that patients could have been 
infected with both HBV and HCV or multiple genotypes. 
We intentionally broadened the inclusion criteria to 
maximise the generalisibility of study results. However, 
cases and controls might not have had comparable durations 
of infection, which is one of the prognostic factors for 
HCC development. It is not adequate to examine just one 
risk factor using multivariate analysis, as HCC is a multi-
factorial disease. Although we initially aimed to examine 
correlations between HBV/HCV genotypes and the 
incidence and mortality of HCC, the necessary information 
was not available.
Conclusions
Conflicting reports on the association between these 
genotypes and HCC make it difficult for clinicians to 
select which patients to monitor or intervene to prevent 
the development of HCC. We nevertheless conclude 
that (1) among HBV carriers, infection with genotype C 
significantly increases the risk of developing HCC compared 
to those without this genotype; (2) among HCV carriers, 
infection with genotype 1b increases the risk of HCC two-
fold compared to controls without this genotype; (3) such 
increased risk should be explained as risk over and above 
the existing risk associated with HBV or HCV infection; 
and (4) HCV genotypes 1a and 2a are associated with a 
decreased risk of developing HCC. However, the clinical 
importance of these findings remain to be determined.
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